WHO ICTRP trial
Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease
ISRCTN59798735 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN59798735 |
|---|---|
| Public title | Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease |
| Primary sponsor | University Medical Center Groningen (UMCG) (The Netherlands) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Netherlands |
| Conditions | Parkinson's disease Nervous System Diseases Parkinson's disease |
| Interventions | Interventions amended as of 05/09/2007: All participants will receive celecoxib oral medication of 100 mg daily for 1 month. Interventions provided at time of registration: Celecoxib oral medication of 100 mg daily for 1 month. |
| Registration date | Jan 5, 2007 |
| Target size | 20 |
| Secondary IDs | 16901 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: